Cell & Gene Therapy Manufacturing Services Market Size, Share, By Type, Workflow, Mode, Indication, Application, and Region - Trends, Analysis, and Forecast till 2035

Cell & Gene Therapy Manufacturing Services Market Size, Share, By Type, Workflow, Mode, Indication, Application, and Region - Trends, Analysis, and Forecast till 2035

Cell & gene therapy manufacturing services encompasses a range of specialized processes and technologies aimed at producing cell-based and gene-based therapies. These services are critical in the biopharmaceutical industry, which focuses on the development and manufacturing of innovative treatments designed to modify genetic material to treat, prevent, and potentially cure diseases. The market is expected to grow due to the surging reliance on contract development and manufacturing organizations (CDMOs) globally.

Report Highlights:

• By 2035, the cell & gene therapy manufacturing services market size is expected to achieve a valuation of USD 42.3 billion.
• In 2024, the market was worth USD 8.4 billion.
• The focused market is expected to witness a steady CAGR of 19.4%.
• North America held the largest share of the market in 2024.
• Asia Pacific is expected to be the fastest-growing region in the market.
• By type, the market is being dominated by the cell therapy segment.
• On the basis of workflow, the cell processing segment is leading the market.
• Based on mode, the market is dominated by the contract manufacturing segment.
• Under indication, the oncology segment holds the largest cell & gene therapy services market share.

Key Highlights:

• In October 2024, Governor Kathy Hochul unveiled plans for New York BioGenesis Park, a groundbreaking USD 430 million Cell and Gene Therapy Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., and this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York state.
• In September 2024, LumaCyte, a leader in advanced cellular analysis and precision bioanalytics, proudly announced the launch of its groundbreaking cell therapy application for predictive CAR T donor analytics. Leveraging its novel Laser Force Cytology technology and Radiance instrument, LumaCyte uncovers deep data insights into highly variable and complex patient and donor cellular starting material, enabling cell therapy developers to predict manufacturing success for specific donors or patients.

Report Analysis:

Acquisition & Partnership:

• For instance, in January 2024, Kyowa Kirin Co., Ltd. a Japan-based global specialty pharmaceutical company (J-GSP) discovering and developing novel medicines utilizing the latest biotechnology, and Orchard Therapeutics plc, a global gene therapy leader, today announced Kyowa Kirin has successfully completed the acquisition of Orchard Therapeutics.

The acquisition of all outstanding shares of Orchard Therapeutics by way of a Scheme of Arrangement procedure under the UK Companies Act 2006 has become a wholly-owned subsidiary of Kyowa Kirin. The integrated business will now increase its focus on meeting the needs of people living with devastating genetic and other severe diseases where the burden is immense and current treatment options are limited or do not exist.

• For instance, in July 2024, Genezen, a best-in-class gene therapy CDMO, announced an agreement to acquire uniQure's commercial gene therapy operations in Lexington, MA, bringing a strategic manufacturing facility and a world-class team of employees to the company.

Under the terms of the agreement, Genezen will enter into strategic supply agreements for uniQure's clinical portfolio and CSL's commercial HEMGENIX product, the first one-time gene therapy approved in the U.S. and Europe for the treatment of adults with severe and moderately severe Hemophilia B. Located just outside of Boston, the Lexington site is a commercially-licensed viral vector facility, enabling Genezen to support customers from preclinical development programs through late-phase and commercial manufacturing.

Browse ∼50 market data tables and ∼45 figures through ∼173 slides and in-depth TOC on “Cell & Gene Therapy Manufacturing Services Market Size, Share, By Type, Workflow, Mode, Indication, Application, and Region - Trends, Analysis, and Forecast till 2035”

Cell & Gene Therapy Manufacturing Services Market Competitive Landscape:

The major players operating in the market are Lonza Group, KBI Biopharma, Inc., Cell Therapies Pty Ltd., RoslinCT, CGT Catapult, ABL, Inc., Batavia Biosciences B.V., Aldevron LLC., Oxford Biomedica USA, Vivebiotech, Rentschler Biopharma, AGC Biologics, ElevateBio, Pharmaron, Recipharm AB, and Exothera.